SEC Form 4 · accession 0001235802-15-000035
UROPLASTY INC · UPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darin Hammers
Officer — Sr VP Global Sales & Marketing
Period of report
Mar 31, 2015
Accepted (ET)
Apr 2, 2015 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000890846
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 31, 2015 | D | 131,800 | — | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.69 | Mar 31, 2015 | D | 100,000 | D | — | Feb 10, 2020 | Common Stock | 100,000 | 0 | D |
Explanation of responses
- F1Consists of 33,333 shares subject to restricted stock assumed by Cogentix Medical, Inc., formerly Vision-Sciences, Inc. ("Cogentix") in the merger agreement between issuer and Cogentix and replaced with 24,219 shares of Cogentix stock valued at $4.09 per share, 75,000 shares subject to restricted stock assumed by Cogentix and replaced with 54,495 shares of Cogentix stock valued at $4.56 per share and 23,467 shares disposed of pursuant to the merger agreement in exchange for 17,052 shares of Cogentix common stock on the effective date of the merger.
- F2This option, which provided for vesting in three almost equal annual installments beginning on February 11, 2014, was assumed by Cogentix in the merger and replaced with an option to purchase 72,661 shares of Cogentix stock for $3.71 per share.